Stocktoria
ASP Isotopes Inc. ASPI
ASP Isotopes Inc. (ASPI) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 0.36% (safety: no dividend). FY2025 revenue was $23.8M at a -670.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.737 |
| Retained earnings / assets | -0.464 |
| EBIT / assets | -0.12 |
| Equity / liabilities | 1.118 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ASPI | ASP Isotopes Inc. | 5/9 | 3.69 | — | — |
| FSI | FLEXIBLE SOLUTIONS INTERNATIONAL INC | 5/9 | 6.24 | 110.2 | +0.7% |
| ARQ | Arq, Inc. | 2/9 | 1.53 | — | +10.4% |
| FTK | FLOTEK INDUSTRIES INC/CN/ | 4/9 | -0.95 | 26.3 | +26.9% |
| WDFC | WD 40 CO | 7/9 | 9.05 | 33.7 | +5% |
| OEC | Orion S.A. | 3/9 | 1.08 | — | -3.8% |
| CBT | CABOT CORP | 6/9 | 4.51 | 14.6 | -7% |
About ASP Isotopes Inc.
ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes in South Africa,Hong Kong, and United States. It operates in two segments, Nuclear Fuels, and Specialist Isotopes and Related Services. The Nuclear Fuels segment focuses on the research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods used to separate high-value, low-volume isotopes, such as C-14, Mo-100 and Si-28, for target end markets, including pharmaceuticals and agrochemicals, nuclear medical imaging, and semiconductors; provision of related services; and operation of PET labs. The company offers the Aerodynamic Separation Process (ASP) technology, which separates gas species and isotopes in a volatile state; and the Quantum Enrichment (QE) technology, which separates isotopes. It also produces and commercializes Molybdenum-100, Molybdenum-98, and Ytterbium-176 for the nuclear medical industry. In addition, the company develops Zinc-68, Nickel-64, and Xenon-129/136 for the nuclear medical industry; Lithium-7, Uranium-235, and Chlorine-37 for the energy industry; and Germanium-70/72/74 for semiconductor markets. The company was incorporated in 2021 and is based in Dallas, Texas.
FAQ
Is ASPI financially healthy?
ASP Isotopes Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does ASPI pay a dividend, and is it safe?
Yes. ASP Isotopes Inc. pays a dividend yielding about 0.36% with a None payout ratio, rated “no dividend” for safety.
How profitable is ASPI?
In FY2025, ASP Isotopes Inc. had a net margin of -670.2% and a return on equity of -60.8%.
What is the analyst price target for ASPI?
The average Wall-Street price target for ASP Isotopes Inc. is $13.00, about 202.3% above the recent price, from 3 analysts (consensus: strong buy).
Is ASPI a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ASP Isotopes Inc.: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a dividend yield of 0.36%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.